Predictive polymorphisms for breast cancer in postmenopausal Mexican women

Sierra-Martínez, Mónica; Hernández‐Cadena, Leticia; García-Sánchez, José Rubén; Acosta-Altamirano, Gustavo; Palacios‐Reyes, Carmen; Alonso-Themann, Patricia García; García-Ortiz, Liliana; Quintas-Granados, Laura Itzel; Reyes-Hernández, Octavio Daniel

doi:10.4103/0973-1482.179109

Cited by 7 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[VIC/FAM]: TCATCTGAGTTCCAAATGT CCCAGC[C/T]GTTTTATGCTTTGTCTCTGTTTCCC. 8 AhR SNP primers, forward 5′-GATTGATTTTG AAGACCTCA-3′ , reverse 5′-CTGAAGGTATGAAG GGAG-3′ , sequence [VIC/FAM]: CTAGGCATTGAT TTTGAAGACATCA[A/G] ACACATGCAGAATGAAAA ATTTTTC 8,9 The PCR reaction mix volume was 10 μl TaqMan Universal PCR Master Mix and 1 μl primer mix were added into each well of a reaction plate. For ease of use, assay mixes were diluted to 20X working solutions with 1X TE buffer (10mM Tris ‫‬ -‫‬HCl, 1 mM EDTA, pH 8.0) and DNase-free water were used.…”

Section: Methodsmentioning

confidence: 99%

Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt

Mohamed

2024

EJI

View full text Add to dashboard Cite

Breast cancer is the most malignant tumor among women in the world. Single nucleotide polymorphisms (SNPs) might better predict breast cancer prognosis. PvuII (T/C substitution), XbaI (A/G substitution), and aryl hydrocarbon (AhR) (G/A substitution) were evaluated as possible genetic prognostic factors for breast cancer. The aim of the current study was to assess the relation between PvuII (rs2234693), XbaI (rs9340799), and aryl hydrocarbon receptor gene polymorphisms AhR (rs2066853) in breast cancer prognosis. This was a case-control study that included 120 breast cancer patients classified into two groups. The first group included 60 patients with good prognostic factors, and the second group included 60 patients with poor prognostic factors. Blood samples were taken from all study participants to perform the genotyping assay. We found that positive genotypes of PvuII, XbaI, and AhR polymorphisms were strongly associated with better prognostic factors for breast cancer patients, while negative genotypes of PvuII and XbaI were more and significantly prevalent in poor prognostic breast cancer patients. We conclude that PvuII T/C, XbaI G/A, and AhR G/A alleles may be prognostic for breast cancer progression. ‎

show abstract

Section: Methodsmentioning

confidence: 99%

Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt

Mohamed

2024

EJI

View full text Add to dashboard Cite

show abstract

“…Analyses of a limited number of candidate variants in hormone receptor genes (estrogen ( ESR1 ), androgen ( AR ), and progesterone receptors ( PGR )) yielded mostly negative results except in secondary stratified analyses (by body mass index or use of hormone replacement therapy) [148,149,150,151,152]. Studies conducted in Latin America focused on the ESR1 , PGR , COMT, CYP19A1 , and CYP1A1 genes [89,113,115,120,150,153]. One of these studies reported a positive association between an Alu insertion in the PGR gene and breast cancer risk [120], while other studies revealed statistically significant associations for polymorphisms within the CYP1A1 gene [113,115].…”

Section: Breast Cancer Candidate Gene Studies In Latin Americamentioning

confidence: 99%

Genetic Epidemiology of Breast Cancer in Latin America

Zavala

Serrano-Gómez

Dutil

et al. 2019

Genes

View full text Add to dashboard Cite

The last 10 years witnessed an acceleration of our understanding of what genetic factors underpin the risk of breast cancer. Rare high- and moderate-penetrance variants such as those in the BRCA genes account for a small proportion of the familial risk of breast cancer. Low-penetrance alleles are expected to underlie the remaining heritability. By now, there are about 180 genetic polymorphisms that are associated with risk, most of them of modest effect. In combination, they can be used to identify women at the lowest or highest ends of the risk spectrum, which might lead to more efficient cancer prevention strategies. Most of these variants were discovered in populations of European descent. As a result, we might be failing to discover additional polymorphisms that could explain risk in other groups. This review highlights breast cancer genetic epidemiology studies conducted in Latin America, and summarizes the information that they provide, with special attention to similarities and differences with studies in other populations. It includes studies of common variants, as well as moderate- and high-penetrance variants. In addition, it addresses the gaps that need to be bridged in order to better understand breast cancer genetic risk in Latin America.

show abstract

Pathological characteristics, survival, and risk of breast cancer associated with estrogen and xenobiotic metabolism polymorphisms in Mexican women with breast cancer

Martínez-Ramírez

Castro-Hernández

Pérez‐Morales

et al. 2021

Cancer Causes Control

View full text Add to dashboard Cite

Predictive polymorphisms for breast cancer in postmenopausal Mexican women

Abstract: The presence of the G/G genotype of XbaI may be considered a susceptibility allele in Mexican women. Due to increased postmenopausal BC risk, the XbaI (WT/G or G/G) alleles may be used as a postmenopausal predictive factor for BC in Mexican women.

Cited by 7 publications

References 41 publications

Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt

Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt

Genetic Epidemiology of Breast Cancer in Latin America

Pathological characteristics, survival, and risk of breast cancer associated with estrogen and xenobiotic metabolism polymorphisms in Mexican women with breast cancer

Contact Info

Product

Resources

About